File ID,Date of Petition,Was_Withdrawn,Submitter,Submitter Type,Petition Cited Statutes or Regulations,FDA Action Commented On,Requested Action,Justification for Request,Final Decision,Number of Interim Responses,Interim Response Date,Last Response Date,Responding FDA Center,Responses Cited Statutes or Regulations,Justification for Interim Response,Justification for Final Response,Cleaned Final Decision,Response Time (Days)
FDA-2017-P-0176,2017-01-09,False,"Kleinfeld, Kaplan and Becker, LLP",law/consulting,"- 21 C.F.R. § 10.30 (Citizen Petition procedures)
- 21 C.F.R. § 101.4(h) (Labeling of dietary supplements)
- 68 Fed. Reg. 51738 (August 28, 2003) – Proposed amendment to 21 C.F.R. § 101.4(h)
- 21 C.F.R. § 25.30 (Environmental impact exclusion)
- 21 C.F.R. § 10.30(b) (Economic impact statement provisions)","The FDA’s proposed amendment to 21 C.F.R. § 101.4(h), specifically the 2003 proposal to replace the incorporated references (1992 edition of Herbs of Commerce and 1994 edition of International Code of Botanical Nomenclature) with their 2000 editions.","AHPA requests that FDA:
1. Withdraw the proposed rule published at 68 Fed. Reg. 51738.
2. Issue an Advance Notice of Proposed Rulemaking (ANPRM) to revise 21 C.F.R. § 101.4(h), suggesting that botanical names on supplement labels be consistent with the Herbs of Commerce, 2nd edition (2000), or other appropriate authoritative references","- The current reference (Herbs of Commerce, 1st ed., 1992) is outdated.
- The 2nd edition (2000) includes standardized common names for ~1,500 more botanicals and updates ~140 names from the 1st edition.
- Plant taxonomy evolves, and new references reflect more accurate nomenclature.
- There is a need for clarity and consistency in naming botanical dietary ingredients to reflect modern commerce and ensure regulatory compliance",,1.0,2/2/2018,2018-02-02,Center for Food Safety and Applied Nutrition (CFSAN),,"The FDA stated the petition is under active evaluation, but decision-making has been delayed due to competing agency priorities ",,no decision,389.0
FDA-2017-P-0508,2017-01-25,False,"Union of Concerned Scientists, Center for Science and Democracy",advocacy/academic,"- 5 U.S.C. § 553(e)
- 21 C.F.R. § 10.25
- 21 C.F.R. § 10.30
- 21 C.F.R. § 101.13
- 21 C.F.R. § 101.14
- 21 C.F.R. § 25.30(h)
- 21 C.F.R. § 10.30(b)(3)
- 21 C.F.R. § 101.65
- 21 U.S.C. § 343
- Sections 201(n), 403A, and 701(a) of the FD&C Act
- Nutrition Labeling and Education Act of 1990","- Current FDA regulations allowing health and nutrient content claims on foods with high added sugar content
- Draft guidance on redefining the “healthy” nutrient content claim","- Amend 21 C.F.R. §§ 101.13 and 101.14 to include a disqualifying nutrient level for added sugars
- Prevent foods with added sugars above the threshold from making health or nutrient content claims","- Scientific evidence links excessive added sugar to chronic diseases (e.g., type 2 diabetes, CVD, obesity)
- Added sugar now has a defined DRV (25g for ages 1–3, 50g for 4+)
- Precedent exists for disqualifying levels for fat, sodium, etc.
- Prevent misleading claims that make sugar-rich foods appear healthy, especially for children
- Supported by over 30,000 individuals nationwide",,1.0,7/17/2017,2017-07-17,Center for Food Safety and Applied Nutrition (CFSAN),,The FDA stated that it has not completed review of the petition due to other agency priorities and limited availability of resources. The Agency committed to notify the petitioner once a decision is reached ,,no decision,173.0
FDA-2017-P-1298,2017-03-02,False,The Good Food Institute (GFI),advocacy/academic,"- 21 C.F.R. § 10.30 (Citizen petition)
- 5 U.S.C. § 553(e) (APA right to petition for rulemaking)
- 21 U.S.C. § 343(a)(1) (FDCA: misbranding due to false or misleading labeling)
- 21 C.F.R. § 101.3(b) (standard of identity for common food names)
- 21 U.S.C. § 321(g) (definition of ""drug"" under FDCA)","GFI comments on recent suggestions that plant-based products should be restricted from using terms like “milk,” “meat,” and “eggs” on their labels. These suggestions imply that plant-based products using such terms are misleading or violate standards of identity.","GFI requests that FDA:
1. Issue a regulation or guidance recognizing that compound terms like “soy milk,” “almond milk,” “vegan cheese,” and “plant-based meat” are not misleading when the plant source is clear.
2. Reaffirm existing labeling rules allowing these terms under current FDA law.","- Terms like “soy milk” and “vegan cheese” have been used for decades and are well understood by consumers.
- Plant-based labeling provides accurate information and facilitates consumer choice.
- Restricting these terms would violate the First Amendment and contradict consumer understanding.
- There is no evidence of consumer confusion over these terms.
- The FDA’s past enforcement policy has tolerated these labels, and no formal standard excludes plant-based variants from common usage names.",,1.0,8/29/2017,2017-08-29,"Center for Food Safety and Applied Nutrition (CFSAN)
",,"- The petition requested FDA to issue regulations clarifying how foods may be named by reference to the names of other foods.
- FDA indicated that it had not yet reached a decision due to competing priorities within the agency.
- They committed to completing review and considering amendments as warranted within the context of other program priorities
",,no decision,180.0
FDA-2017-P-1359,2017-03-06,False,"Pharmaceutical Manufacturing Research Services, Inc. (PMRS)",industry/corporation,"- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31
- Section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)","The FDA’s approval and labeling of:
- OxyContin’s indication for chronic pain
- All extended-release opioids indicated for chronic pain
- All immediate-release opioids used for chronic pain","PMRS requests that the FDA:
(i) Revoke OxyContin's approval for chronic pain
(ii) Revoke approval of all ER opioids for chronic pain
(iii) Revoke IR opioid labeling supporting chronic pain use","- FDA approved chronic pain indication for OxyContin without substantial evidence
- Misuse, addiction, and overdose risks have increased
- Chronic pain indication contradicts scientific data and public health findings
- OxyContin was originally approved only for acute use; later changes led to widespread abuse
- The change contributed to the opioid epidemic; over 200,000 deaths cited",,1.0,8/31/2017,2017-08-31,"Center for Drug Evaluation and Research (CDER)
",,"- The petition requested the FDA to revoke certain labeling approvals related to both extended-release and immediate-release opioid products, specifically seeking revocation of:
1. OxyContin’s chronic use labeling
2. ER opioids for chronic pain
3. IR opioids for chronic pain
4. Replace IR labeling with indications for acute pain only.
- FDA explained that the petition raised significant and complex issues requiring extensive internal review and analysis by agency officials. Hence, an interim response was issued pending further evaluation
",,no decision,178.0
FDA-2017-P-1391,2017-03-03,False,"Epstein Becker & Green, P.C.",law/consulting,"- 21 C.F.R. § 10.30 (Citizen Petition)
- 21 C.F.R. § 10.75 (Internal agency review procedures)
- 21 C.F.R. § 3.8 (Letter of designation rules)
- 21 C.F.R. § 25.30 (Environmental impact exclusion)
- 5 U.S.C. §§ 555(b), 706(1), 706(2)(A) (Administrative Procedure Act)
- 21 U.S.C. § 353(g) (FDCA designation provisions)
- 21st Century Cures Act, Sec. 3038","The petition comments on the lack of a regulatory timeline for appeals of FDA’s letter of designation decisions made by the Office of Combination Products under 21 C.F.R. § 3.8.
","- Amend 21 C.F.R. § 3.8 to include a new subsection (d): FDA must complete review of appeals under 21 C.F.R. § 10.75 within 60 calendar days.
- Require all pending appeals submitted prior to October 1, 2015, to be resolved by March 9, 2017","- Significant delays (some over 17 months) in decision-making due to lack of timelines.
- Delays violate the Administrative Procedure Act by allowing “arbitrary” and untimely decisions.
- Delays hinder correction of errors in designation decisions and delay compliance with the 21st Century Cures Act.
- Innovators lose patent time and are forced to accept erroneous designations.
- Most importantly, delays harm public health by slowing patient access to new therapies",,,,,,,,,no decision,
FDA-2017-P-1463,2017-03-08,False,Tate & Lyle Ingredients Americas LLC,industry/corporation,"- 21 C.F.R. § 10.30 (Citizen Petition provision)
- 21 C.F.R. § 101.9(c)(1)(i) (caloric value labeling regulation)
- 21 C.F.R. § 25.31 (Environmental impact exclusion)","The petition comments on FDA's regulation of caloric values listed on nutrition labels, specifically requesting a rulemaking amendment to 21 C.F.R. § 101.9(c)(1)(i) to define a new caloric value for Allulose.
","The petitioner requests that FDA:
1. Amend 21 C.F.R. § 101.9(c)(1)(i) to specify that Allulose contributes 0.2 kcal/g and list it under a new subsection (G).
2. Set the amendment’s effective date 30 days after Federal Register publication.
3. Set the compliance date two years post-publication (three years for small manufacturers). ","- Scientific evidence, including a radiotracer metabolism study conducted by Tate & Lyle, demonstrated that Allulose is absorbed but not metabolized, and is excreted largely intact, contributing 0.2 kcal/g or less.
- The Iida et al. (2010) study estimated the caloric value between 0.20–0.39 kcal/g, supporting Tate & Lyle's position.
- A rigorous human 14C-labeled radiotracer study showed over 80% urinary recovery, minimal fecal excretion, and negligible 14CO2 in breath, confirming no significant metabolism.
- Animal studies (e.g., Matsuo 2002) supported these findings, showing Allulose’s energy deposition efficiency was only 0.3% of sucrose.
- The petitioner emphasizes that labeling Allulose at 0.2 kcal/g reflects the most scientifically accurate and conservative value based on current data. ",,,,,,,,,no decision,
FDA-2017-P-2164,2017-04-05,False,Steptoe & Johnson LLP,law/consulting,"- 21 C.F.R. §§ 10.25, 10.30, 10.33, 10.35
- 21 U.S.C. § 343(q)(5)(H)
- 5 U.S.C. § 553(b)(B), § 706
- Administrative Procedures Act (APA)
- Executive Order 13771
- Executive Order 13777 ","The Final Rule on Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments (79 Fed. Reg. 71156, Dec. 1, 2014) 
","- Stay the effective date of the Final Rule (under 21 C.F.R. § 10.35(b))
- Reconsider the Final Rule and commence a new rulemaking process under section 4205 of the ACA (21 U.S.C. § 343(q)(5)(H))","- Impossibility of Compliance: Petitioners cite ambiguity in definitions (e.g., what constitutes a ""menu""), unaddressed compliance guidance, and unfeasible implementation timelines.
- Underestimated Costs: FDA underestimated compliance costs for non-restaurant retailers, which are in the hundreds of millions to billions of dollars.
- Overreach and Improper Scope: The Final Rule extends beyond what Congress intended by applying to businesses not “similar” to restaurants.
- First Amendment Concerns: The rule mandates potentially misleading commercial speech and fails to directly advance a substantial government interest.
- Inconsistency with Federal Policy: The Final Rule conflicts with executive directives aimed at reducing regulatory burdens on businesses. ",,1.0,6/29/2017,2017-06-29,"Center for Food Safety and Applied Nutrition (CFSAN)
",,"- The petition requested a stay and reconsideration of the FDA’s final rule on “Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments.”
- FDA explained that they were still reviewing the petition and that they had already extended the compliance date for the rule to May 7, 2018 (as published in the Federal Register on May 4, 2017, 82 Fed. Reg. 20825).
- FDA also noted they were extending the comment period on the interim final rule by another 30 days and encouraged further comments
",,no decision,85.0
FDA-2017-P-3352,2017-05-25,False,"Belcher Pharmaceuticals, LLC",industry/corporation,"- 21 C.F.R. § 10.30 (Citizen petition procedure)
- 21 C.F.R. § 201.22(c) (Current sulfite warning regulation)
- 21 C.F.R. §§ 201.57, 201.100(d) (Labeling requirements)
- 21 C.F.R. § 25.31 (Environmental impact exclusion)
- Historical references: 50 Fed. Reg. 47,558 (1985); 51 Fed. Reg. 43,904 (1986)",FDA’s regulation in 21 C.F.R. § 201.22(c) that mandates the current sulfite warning labeling for epinephrine injection products used in emergency allergic situations.,"Amend 21 C.F.R. § 201.22(c) to update the sulfite warning language for epinephrine injections used in emergency situations. The updated warning should:
- Reflect the availability of sulfite-free epinephrine formulations.
- Avoid misleading implications that only sulfite-containing or non-epinephrine options exist.
- Emphasize that sulfite-free products should be used when available.","- The current regulation, written in 1986, is outdated and misleading; it implies no sulfite-free alternatives exist.
- Belcher's own sulfite-free epinephrine formulation (approved NDA 205029) has been FDA-approved and commercially available since 2014.
- Sulfite-sensitive patients are at risk from metabisulfite-containing formulations (e.g., Adrenalin®, EpiPen®), which can cause symptoms resembling or compounding anaphylaxis.
- Repeat dosing can exacerbate sulfite reactions and diminish drug efficacy.
- Sulfonate formation and metabolite persistence in the body can lead to delayed anaphylactic symptoms after treatment.
- Historical case studies show serious and prolonged adverse effects linked to sulfite-containing treatments.
- Physicians and patients need accurate labeling to make informed choices in emergencies, especially where safer alternatives are available",,,,,,,,,no decision,
FDA-2017-P-3413,2017-05-23,False,Salter Labs,advocacy/academic,"- 21 C.F.R. § 10.30 (Citizen petition procedure)
- 21 U.S.C. § 360c(e) (Section 513(e) of the FDCA – reclassification of devices)",FDA’s classification of oxygen conservers as Class II (special controls) medical devices.,The petitioner requests that the FDA reclassify oxygen conservers from Class II to Class I (general controls) devices .,"- Long-standing safety record of oxygen conservers over several decades.
- No documented safety or effectiveness concerns specific to the devices currently on the market.
- Current classification imposes unnecessary regulatory burdens that do not correspond to actual risk.
- Reclassification to Class I would align with the FDA’s goal of risk-based regulation and focus resources on higher-risk devices.
- Petition references 21 U.S.C. § 360c(e) as the legal basis for requesting reclassification when new information is available showing that special controls are unnecessary .",,,,,,,,,no decision,
FDA-2017-P-4027,2017-07-01,False,Strides Pharma Inc.,industry/corporation,"- 21 C.F.R. § 10.25(a)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31",Determination of whether METICORTEN (Prednisone) Tablets 1 mg and 5 mg (NDA N009766) were withdrawn from sale for reasons of safety or effectiveness,"- Determine whether METICORTEN (Prednisone) Tablets 1 mg was discontinued for safety or efficacy reasons
- If not, accept ANDA 210785 for Prednisone Tablets USP 1 mg for filing and approval using METICORTEN as the reference listed drug (RLD)","- METICORTEN Tablets are listed as ""Discontinued"" in the FDA's Orange Book without a stated reason
- The petitioner seeks clarity on whether the discontinuation was for safety or effectiveness reasons, as required for ANDA referencing
- Other generics for Prednisone 1 mg are already on the market, implying potential approval viability",,,,,,,,,no decision,
FDA-2017-P-4039,2017-07-03,False,Center for Lawful Access and Abuse Deterrence (CLAAD),law/consulting,"- 21 U.S.C. § 355(e) (FDCA section 505(e))
- 21 C.F.R. §§ 314.162, 5.10, 5.82
- 21 C.F.R. §§ 25.30(h), 25.31(h) (for environmental exclusion)","The petition comments on FDA’s current policy regarding the continued approval and marketing of non-abuse-deterrent opioid analgesics, and requests a change in enforcement to mandate conversion to abuse-deterrent formulations (ADOs).
","The petitioner asks the FDA to:
- Require manufacturers of certain non-abuse-deterrent oral opioid analgesics to convert to abuse-deterrent opioids (ADOs) within three years of the approval of a third ADO with the same active moiety.
- Remove products that are not converted within that time frame from the market.","- To mitigate the opioid overdose epidemic.
- To align with federal policy goals including those expressed by the Trump Administration and the FDA’s Opioids Action Plan.
- To address the public health and economic burden of opioid misuse and abuse.
- Because scientific advancements in ADOs and regulatory precedents (e.g., ER oxycodone case) support such a transition.",,1.0,12/28/2017,2017-12-28,Center for Drug Evaluation and Research (CDER),,"The FDA states that the petition raises “complex issues requiring extensive review and analysis by Agency officials.” Therefore, a decision has not yet been reached.

",,no decision,178.0
FDA-2017-P-4145,2017-07-07,False,Mylan Pharmaceuticals Inc.,industry/corporation,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact categorical exclusion)","The petition comments on the FDA’s current classification of azacitidine injectable products, specifically the dosage strength of the Reference Listed Drug (RLD), Vidaza® (100 mg/vial), and seeks permission to submit a 50 mg/vial product under an ANDA (Abbreviated New Drug Application).
","To permit the submission of an ANDA for Azacitidine for Injection, 50 mg/vial, based on the approved RLD Vidaza® 100 mg/vial, reflecting a change in strength while maintaining the same proportion of active and inactive ingredients.
","- The change in strength (100 mg/vial to 50 mg/vial) is allowed under FDA regulations if it maintains proportionality with the RLD.
- The lower strength would provide greater dosing flexibility for physicians, based on hematological values.
- No concerns about safety or efficacy, as both products would be quantitatively and qualitatively equivalent.
- No change in route of administration or formulation—just a reduction in concentration and volume, with preserved proportions.",,,,,,,,,no decision,
FDA-2017-P-4389,2017-07-21,False,"Wildway, LLC",industry/corporation,"- 21 C.F.R. § 101.60(c)(2)(v)
- Section 403(r)(4) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 101.60(b)
- 21 C.F.R. § 101.60(c)(2)(i–iv)
- 21 C.F.R. § 101.9(g)
- 21 C.F.R. § 25.32 (including § 25.32(p))",Regulation requiring products labeled with “No added sugar” to also include a statement that the product is not “low calorie” and to refer consumers to the nutrition panel,"To exempt certain Wildway food products from the requirement under 21 C.F.R. § 101.60(c)(2)(v) to declare:
> “The product bears a statement that the food is not ‘low calorie’ or ‘calorie reduced’ ... and that directs consumers' attention to the nutrition panel.”","- The new Nutrition Facts label (effective May 2016) already requires declaration of added sugars and their % Daily Value, rendering the additional statement redundant.
- The term “No added sugars” is consistent with the nutrition facts panel when it states “Includes 0g Added Sugars.”
- Requiring the extra disclaimer clutters the label and may mislead or confuse consumers.
- No products in the granola or cereal categories reasonably qualify as “low calorie” per 21 C.F.R. § 101.60(b); requiring a disclaimer for something that is clearly not expected misleads more than informs.
- FDA’s own statements support limiting excessive label information to avoid overwhelming consumers.
- Added sugars are a required declaration, not a claim, and should not require additional disclaimers.
- Wildway asserts this added disclaimer constitutes unnecessary regulatory burden with no public health benefit",,,,,,,,,no decision,
FDA-2017-P-4575,2016-11-15,False,Unilever,industry/corporation,"- 21 C.F.R. § 101.70 (Health Claims; Petitions)
- Section 403(r)(3)(B)(i) of the Federal Food, Drug, and Cosmetic Act (FFDCA)","FDA's regulatory framework for approving health claims related to dietary fats and oils, particularly concerning the relationship between unsaturated fatty acids and coronary heart disease risk","Approve a new health claim stating that oils high in unsaturated fats may reduce the risk of coronary heart disease when replacing saturated fat, as part of a healthy diet
","- Scientific evidence supports a favorable association between dietary intake of unsaturated fatty acids and reduced risk of coronary heart disease (CHD).
- The petition includes over 80 peer-reviewed human intervention and observational studies.
- FDA had previously approved a similar claim for canola oil, and this request seeks to broaden it to include soybean, sunflower, corn, and other vegetable oils.
- Approval would improve public health messaging by aligning dietary guidance with regulatory standards",,1.0,8/4/2017,2017-08-04,"Center for Food Safety and Applied Nutrition (CFSAN)
",,"Not Provided – This is an interim response only confirming the petition was filed. No substantive justification or evaluation is included.
",,no decision,262.0
FDA-2017-P-5082,2017-08-18,False,"ChromaDex, Inc.",industry/corporation,"- 21 C.F.R. §§ 10.25, 10.30 (Citizen petition procedure)
- 21 U.S.C. § 342(a)(1), 342(f), 342(f)(1)(B), 350b (Adulterated foods & new dietary ingredients)
- 21 U.S.C. §§ 332, 334 (Enforcement mechanisms: injunction & seizure)
- 21 C.F.R. § 190.6 (New Dietary Ingredient Notification)
- 21 C.F.R. § 173 Subpart C (Food additives: solvents)
- 21 C.F.R. § 25.32 (Environmental impact exclusion)","Continued marketing and distribution of Elysium Health’s Basis product, alleged to contain undeclared toluene and an unapproved new dietary ingredient","- Declare Basis adulterated under 21 U.S.C. § 342
- Halt distribution and seize product
- Enjoin manufacturers/distributors under 21 U.S.C. §§ 332, 334
- Determine the unapproved ingredient (nicotinamide riboside) violates 21 U.S.C. § 350b, due to lack of NDI filing","- Laboratory analysis revealed Basis contains 96–144 mg/kg of toluene, a toxic industrial solvent not approved for ingestion
- Elysium switched to a non-NIAGEN® nicotinamide riboside supplier with no FDA-recognized GRAS or NDIN
- Chemical, packaging, and compositional discrepancies were confirmed through testing (e.g., solvents, impurities, metals, label differences)
- Petition argues Elysium has not met FDA’s safety requirements for new dietary ingredients and is selling a product potentially injurious to health",,1.0,2/15/2018,2018-02-15,Center for Food Safety and Applied Nutrition (CFSAN),,"The FDA has not made a decision on the petition within the first 180 days due to competing agency priorities. However, the petition is currently under active evaluation
",,no decision,181.0
FDA-2017-P-5118,2017-08-18,False,"Gluten Free Watchdog, LLC",industry/corporation,"- Section 201(n), 301–303, and 403(a)(1) of the Federal Food, Drug, and Cosmetic Act (FFDCA); 21 U.S.C. §§ 321(n), 331–333, and 343(a)(1)
- 21 C.F.R. Part 101.91 (Gluten-Free Labeling Rule)","Enforcement and compliance efforts under the Gluten-Free Labeling Rule, particularly relating to the labeling of products that are “gluten-free” despite containing prohibited ingredients such as barley malt, malt extract, and wheat
","- Establish a specific protocol for increased surveillance, investigation, and enforcement of “Facial Misbranding” violations under the Gluten-Free Labeling Rule
- Implement an online reporting system for consumers to submit label violations
- Issue FDA Warning Letters within 30 days of receiving reports
- Alternatively, initiate a “Facial Misbranding Initiative” akin to the Front of Package Labeling Initiative","- Persistent misbranding issues with gluten-free labeled products that actually contain gluten ingredients
- Current consumer reporting mechanisms are inadequate and not prioritized
- Misbranded products remain on shelves despite FDA awareness
- Enhanced enforcement is essential for protecting individuals with celiac disease
- A structured and visible FDA protocol will deter violations and ensure labeling compliance",,1.0,2/13/2018,2018-02-13,Center for Food Safety and Applied Nutrition (CFSAN),,"The FDA has not reached a decision on the petition due to competing agency priorities. The agency states the petition is currently under active evaluation by its staff
",,no decision,179.0
FDA-2017-P-5335,2017-08-29,False,ANDA Consultants,law/consulting,"- 21 C.F.R. § 10.25(a)(2)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.122
- 21 C.F.R. § 314.161
- 21 C.F.R. § 25.31 (categorical exclusion – environmental impact)
- 21 C.F.R. § 10.30(b) (economic impact disclosure)","The status in the Orange Book of Nexiclon™ XR (clonidine) Extended Release Tablets, NDA 22-500, which is listed as discontinued. The petitioner questions whether this discontinuation was due to safety or effectiveness reasons","The petitioner asks the FDA to determine that NDA 22-500 was not withdrawn for reasons of safety or effectiveness, so that it can be used as a reference listed drug (RLD) in ANDA submissions","- NDA 22-500 (Nexiclon™ XR) is currently in the Discontinued section of the Orange Book.
- The petitioner asserts there is no indication that the discontinuation was due to safety or efficacy concerns.
- A formal FDA determination is needed so that generic applicants can reference this NDA in their ANDAs",,,,,,,,,no decision,
FDA-2017-P-5396,,False,"Multiple co-signatories:  Andrew Kolodny, M.D., Executive Director, Physicians for Responsible Opioid Prescribing (PROP)  Jay Butler, M.D., President, Association of State and Territorial Health Officials  Deborah A.P. Hersman, President & CEO, National Safety Council  Charles McKay, M.D., FACMT, President, American College of Medical Toxicology  Judy Rummler, Chair, FED UP! Coalition  Gary Mendell, Founder and CEO, Shatterproof",advocacy/academic,"- 21 C.F.R. § 10.30 (citizen petition regulation)
- 21 U.S.C. § 355(e) (section of the FD&C Act governing drug withdrawal)
- 21 C.F.R. § 25.31(a) (environmental impact categorical exclusion)
- Executive documents and public health reports also cited for context (e.g., CDC guidelines, National Academies recommendations)","The continued market availability of ultra-high dosage unit (UHDU) orally and transmucosally administered opioid analgesics, such as OxyContin 80 mg, IR oxycodone 30 mg, and others with daily doses exceeding 90 MME/day","The petitioners request that the FDA:
- Immediately seek removal of UHDU oral and transmucosal opioid analgesics from the U.S. market
","- UHDU opioids exceed safe dosing levels (CDC: >90 MME/day).
- They pose high risks for misuse, accidental overdose, and death, especially among opioid-naïve users, children, and adolescents.
- Studies show increased risk of overdose, addiction, and other adverse events at high dosages without proportional benefits in pain control.
- Removing UHDUs could reduce morbidity and mortality, reverse risky prescribing norms, and have minimal burden on legitimate patients, who can use smaller doses or alternative formulations (e.g., liquids, patches).
- Aligns with FDA’s new benefit-risk framework that weighs public health impact of misuse",,1.0,2/28/2018,2018-02-28,"Center for Drug Evaluation and Research (CDER)
",,"The petition raises significant issues that require extensive review and analysis by FDA officials. The Agency has not yet reached a decision but will respond once it does
",,no decision,
FDA-2017-P-5592,2017-09-06,False,International Isotopes Inc.,industry/corporation,"- Section 505(j) of the FD&C Act
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.93
- 21 C.F.R. § 25.31 (environmental exclusion)
- 21 C.F.R. § 10.30(b) (economic impact disclosure)","The listing status of Sodium Iodide I-123 Solution, 2 mCi/ml, NDA 017630 in the Orange Book, specifically whether its discontinuation was due to safety or efficacy concerns","Request for FDA to:
- Determine that Sodium Iodide I-123 Solution (2 mCi/ml, NDA 017630) was not discontinued for safety or efficacy reasons
- Publish this determination in the Federal Register
- Amend the Orange Book to list the product as a Reference Listed Drug (RLD)","- Product is listed as discontinued but no evidence indicates GE Healthcare discontinued it for safety or efficacy reasons.
- Petitioner cites FDA’s policy of designating market leaders as RLDs.
- The solution form offers more flexible dosing than fixed-dose capsules (100/200 µCi).
- The proposed manufacturing method would improve the purity of the radioactive product.
- There is currently no RLD available for ANDA applicants for this solution strength, hindering generic development
",,1.0,3/8/2018,2018-03-08,"Center for Drug Evaluation and Research (CDER)
",,"The FDA has not reached a decision due to the need to address other agency priorities. The petition, which requested a determination that Sodium Iodide I-123 oral solution was not discontinued for safety or effectiveness reasons, is still under review
",,no decision,183.0
FDA-2017-P-6211,,False,DSM Nutritional Products LLC,industry/corporation,"- 5 U.S.C. § 553(e) (Administrative Procedure Act)
- 21 C.F.R. §§ 10.25 and 10.30
- Sections 201(n), 403A, and 701(a) of the Federal Food, Drug, and Cosmetic Act
- 21 C.F.R. § 101.9(c)(8)(v) (subject of amendment request)
- Also referenced within text: 21 C.F.R. §§ 104.20, 101.36, 172, 182, 184, 107.10, 130–169","Existing FDA regulations that require complex chemical nomenclature on Nutrition and Supplement Facts labels and Ingredient Declarations.
","DSM requests that the FDA amend 21 C.F.R. 101.9(c)(8)(v) to allow for the use of simple vitamin letter names (e.g., Vitamin C, B1, B2) on Nutrition/Supplement Facts labels and Ingredient Declaration lines
","- Consumers are confused by chemical names (e.g., “ascorbic acid” vs. “Vitamin C”)
- Surveys show consumers rate chemical names as less healthy or are unaware of their meaning
- Simple names improve clarity and recognition of nutrient-fortified products
- Simplified labels reduce space and increase appeal and trust in products
- Harmonizes label language between Nutrition Facts and Ingredient Declaration
- Promotes consumption of nutrient-dense foods and public health",,1.0,4/19/2018,2018-04-19,"Center for Food Safety and Applied Nutrition (CFSAN)
",,"Due to other agency priorities and limited availability of resources, the FDA was unable to reach a decision within 180 days of receiving the petition.

",,no decision,
FDA-2017-P-6357,2016-09-15,False,Diana Wierzchos,individual,"- The petition is submitted under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act (no specific sections cited)
","The petitioner calls for the FDA to reform the U.S. food supply system, specifically regarding factory farming practices. The action is not in response to a specific FDA policy but a general petition to influence national food regulation standards, animal treatment policies, and public health considerations
","- Replace or drastically reduce the use of concentrated animal feeding operations (CAFOs)
- Promote alternative, humane food production methods that are more sustainable and health-conscious
- Encourage legal reform to improve environmental, human, and animal health outcomes
- Address problems associated with subsidized factory farming","- Health risks: Links between red meat consumption and chronic diseases (e.g., cancer, diabetes, cardiovascular conditions)

- Food safety: Issues with contamination and poor hygiene in meat processing (e.g., fecal bacteria, TMAO production, drug-resistant infections)
- Environmental impact: CAFOs generate significant greenhouse gas emissions, deforestation, and water/soil pollution

- Animal welfare: Inhumane treatment, high animal mortality, and lack of rights protections
- Economic & social concerns: Industrial farming undermines small farms and consumer rights; supports unsustainable systems with public subsidies
- The petitioner urges the FDA to address these interconnected issues systemically.",,,,,,,,,no decision,
FDA-2017-P-6631,2017-11-27,False,Amin Talati Upadhye LLP,law/consulting,"- 21 C.F.R. §§ 10.25 and 10.30 (Citizen petition authority)
- 21 U.S.C. § 321(ff)(1) (definition of dietary supplement)
- 21 U.S.C. §§ 343, 301(a), 332, 334 (misbranding, adulteration, injunctions, seizure)
- 21 U.S.C. § 350b (new dietary ingredient - NDI)
- 21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), 355(b), 352(f)(1), 352(o), 360, 351(a)(2)(B) (drug definition, unapproved drugs, misbranding, GMPs)
- 21 C.F.R. § 25.32 (environmental exemption)","FDA’s lack of regulatory enforcement against Cardax Inc. regarding its sale of ZanthoSyn, a product alleged to be misbranded, adulterated, and an unapproved new drug containing synthetic astaxanthin. The petitioner argues FDA should not allow the product to be marketed as a dietary supplement or drug without proper approval or safety evaluation","- Determine ZanthoSyn is misbranded under 21 U.S.C. § 343 (not a dietary supplement)
- If considered a supplement, declare it adulterated due to unnotified new dietary ingredient (NDI)
- Declare ZanthoSyn is an unapproved new drug under 21 U.S.C. §§ 321(g), 355(b), 331(d)
- Take enforcement actions under 21 U.S.C. §§ 332, 334 (injunction, seizure)
- Require Cardax to cease distribution of ZanthoSyn","- Synthetic astaxanthin is not a lawful “dietary ingredient” under the FD&C Act; it is neither derived from natural botanical sources nor part of the conventional food supply.
- Even if considered a dietary ingredient, it is an NDI without notification, and no sufficient safety evidence exists.
- ZanthoSyn bears drug-like disease claims (e.g., anti-inflammatory, cholesterol lowering), making it an unapproved new drug.
- The safety and efficacy of synthetic astaxanthin is unproven, with claims based on unrelated studies.
- Consumers are misled by “physician endorsed” and “safe” claims, increasing public health risk
",,,,,,,,,no decision,
FDA-2017-P-6751,2017-12-05,False,Capstone Law APC,law/consulting,"- 21 U.S.C. § 343 (FDCA § 403)
- 21 C.F.R. § 10.60
- 21 C.F.R. § 101.3(e)
- 21 C.F.R. § 101.3(e)(4)
- 21 C.F.R. § 130.10
- 21 C.F.R. §§ 25.30–25.34 (environmental exclusions)
- 21 C.F.R. § 101.9
- Section 401 of the FDCA","FDA’s regulatory approach and lack of enforcement concerning the labeling of non-dairy milk alternatives (specifically Silk Almondmilk) as “imitation milk”, and whether FDA will accept or reject a court referral for guidance in the matter
","FDA is requested to:
1. Determine or issue guidance on whether Silk Almondmilk ""substitutes for, resembles, and is nutritionally inferior to"" milk.
2. Require it to be labeled as “imitation milk” under 21 C.F.R. § 101.3(e).
3. Promptly respond to the court referral under 21 C.F.R. § 10.60 from a related class action lawsuit","- Silk Almondmilk resembles and substitutes for milk in packaging, placement, advertising, and usage.
- It is nutritionally inferior to dairy milk across essential nutrients including protein, magnesium, potassium, phosphorus, zinc, and several vitamins (as shown in a detailed nutritional comparison table on page 6).
- Consumers are misled by use of the term “milk” in the product’s identity despite its inferiority.
- FDA precedent and prior guidance support labeling such products as “imitation” when they fail to meet nutritional equivalency.
- Regulatory clarity is needed as courts have deferred to FDA on these labeling issues",,1.0,6/7/2018,2018-06-07,"Center for Food Safety and Applied Nutrition (CFSAN)
",,The FDA stated it could not reach a decision within 180 days of the petition’s receipt or by the date of the letter due to other competing agency priorities. The agency will continue reviewing the petition and consider issuing guidance as warranted within the context of other program priorities,,no decision,184.0
FDA-2017-P-6805,2017-12-08,False,Bracco Diagnostics Inc.,industry/corporation,"- Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- 21 C.F.R. § 10.30
- 21 C.F.R. § 314.127(a)(6)(i)
- 21 C.F.R. § 314.430(a)
- 21 C.F.R. § 314.161(a)(1)",The agency’s potential acceptance or approval of ANDAs referencing the discontinued two-ingredient formulation of KINEVAC for injection.,"FDA should:
- Determine the two-ingredient KINEVAC formulation was withdrawn for safety and efficacy reasons.
- Conclude the old formulation is not a suitable RLD.
- Reject any ANDA referencing the discontinued KINEVAC formulation ","- The old two-ingredient formulation was unstable and prone to degradation, risking inaccurate diagnoses and unnecessary surgeries.
- The currently marketed formulation is significantly more stable and does not require overages.
- The older formulation had higher levels of impurities, posing safety concerns.
- Diagnostic standards (e.g., SNM guidelines for gallbladder function using GBEF) were established using the current formulation; using the older one could lead to false positives and improper surgeries.
- Continued use of the old formulation risks public health by undermining the safety and effectiveness of diagnostic procedures",,1.0,5/31/2018,2018-05-31,Center for Drug Evaluation and Research (CDER),,"The FDA stated that the petition raises complex issues requiring extensive review and analysis by agency officials. As such, they were unable to make a final decision at the time and issued this interim response per regulatory requirements
",,no decision,174.0
FDA-2017-P-6967,2017-12-08,False,Natural Products Association (NPA) and Bergstrom Nutrition,advocacy/academic,"- Section 111.75(a)(1) of the Federal Food, Drug, and Cosmetic Act (FDC Act)
",The petition addresses the FDA’s 100 percent identity testing requirement for dietary ingredients in dietary supplement manufacturing,"The petitioners request that the FDA exempt dietary supplement manufacturers using OptiMSM® (from Bergstrom Nutrition) from the 100 percent identity testing requirement for dietary ingredients
","- OptiMSM® is a well-characterized ingredient with a consistent identity profile produced under strict manufacturing controls.
- The petition argues that redundant testing imposes unnecessary regulatory burden and cost.
- Petitioners suggest that a robust supplier verification program and validated Certificates of Analysis (CoAs) should suffice to confirm identity.
- They highlight long-term use, product consistency, and quality assurance procedures in place at Bergstrom Nutrition.
- The exemption would help reduce testing requirements without compromising product quality or safety
",,,,,,,,,no decision,
FDA-2017-P-7031,2017-12-22,False,"JR Rapoza Associates, Inc.",industry/corporation,"- 21 CFR § 10.20
- 21 CFR § 10.30
- 21 CFR § 314.161
- 21 CFR § 25.31 (environmental exclusion)","The petition addresses the lack of a currently marketed Reference Standard (RS) drug product for Thiamine Hydrochloride Injection 100 mg/ml, NDA 0080556, which was discontinued but not for safety/efficacy reasons. It seeks a new RS designation in the Orange Book","The petitioner requests that the FDA designate a new Reference Standard (RS) drug in the Orange Book for Thiamine Hydrochloride Injection 100 mg/ml in a vial to enable submission of bioequivalent ANDAs
","- The original RS product (NDA 0080556 by Fresenius Kabi, USA, LLC) was discontinued for reasons other than safety or efficacy.
- Current FDA guidance allows for designation of a new RS for discontinued drugs.
- Other bioequivalent Thiamine Hydrochloride products are approved and could serve as RS.
- Availability of a designated RS will facilitate ANDA submissions for generic injectable products.
- The larger volume vial offers economic and dosing convenience benefits for healthcare providers",,,,,,,,,no decision,
FDA-2017-P-7034,2017-12-19,False,Jubilant Generics Limited,industry/corporation,"- 21 U.S.C. § 355(j)(2)(C) (FDC Act)
- 21 C.F.R. § 314.93
- 21 C.F.R. § 10.20
- 21 C.F.R. § 10.30
- 21 C.F.R. § 25.31 (Environmental Impact exclusion)","FDA's approach to determining whether a drug product that differs in strength from an RLD (Valtrex®) can be considered suitable for an ANDA submission
","A formal determination by the FDA that Valacyclovir Hydrochloride Oral Tablet EQ 250 mg and 750 mg base is suitable for submission as an Abbreviated New Drug Application (ANDA)
","- Proposed strengths share same indication, dosage form, and route of administration as the RLD
- Strengths (250 mg & 750 mg) are reflected in RLD labeling
- No new safety/efficacy concerns
- Better palatability and dosing flexibility for pediatric and geriatric patients
- Current tablets (500 mg unscored, 1 g partially scored) do not allow individualized dosing
- No clinical trials needed due to established precedent and labeling data
- 250 mg strength already marketed in UK by GLAXOSMITHKLINE",,,,,,,,,no decision,
